- Home
- PNF vs IMMX Comparison
PNF vs IMMX Comparison
Compare PNF & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNF
- IMMX
- Stock Information
- Founded
- PNF 2001
- IMMX 2014
- Country
- PNF United States
- IMMX United States
- Employees
- PNF N/A
- IMMX N/A
- Industry
- PNF Finance Companies
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- PNF Finance
- IMMX Health Care
- Exchange
- PNF Nasdaq
- IMMX Nasdaq
- Market Cap
- PNF 53.5M
- IMMX 50.1M
- IPO Year
- PNF N/A
- IMMX 2021
- Fundamental
- Price
- PNF $6.85
- IMMX $1.71
- Analyst Decision
- PNF
- IMMX Strong Buy
- Analyst Count
- PNF 0
- IMMX 1
- Target Price
- PNF N/A
- IMMX $7.00
- AVG Volume (30 Days)
- PNF 29.1K
- IMMX 40.8K
- Earning Date
- PNF 01-01-0001
- IMMX 05-08-2025
- Dividend Yield
- PNF 5.17%
- IMMX N/A
- EPS Growth
- PNF N/A
- IMMX N/A
- EPS
- PNF N/A
- IMMX N/A
- Revenue
- PNF N/A
- IMMX N/A
- Revenue This Year
- PNF N/A
- IMMX N/A
- Revenue Next Year
- PNF N/A
- IMMX N/A
- P/E Ratio
- PNF N/A
- IMMX N/A
- Revenue Growth
- PNF N/A
- IMMX N/A
- 52 Week Low
- PNF $6.37
- IMMX $1.26
- 52 Week High
- PNF $9.06
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- PNF 30.75
- IMMX 53.28
- Support Level
- PNF $6.65
- IMMX $1.57
- Resistance Level
- PNF $7.03
- IMMX $1.57
- Average True Range (ATR)
- PNF 0.16
- IMMX 0.15
- MACD
- PNF -0.02
- IMMX 0.02
- Stochastic Oscillator
- PNF 20.41
- IMMX 90.24
About PNF PIMCO New York Municipal Income Fund
PIMCO New York Municipal Income Fund is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund's portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.